AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Faruqi & Faruqi Investigates Novo Nordisk Securities Litigation
ByAinvest
Friday, Aug 22, 2025 9:41 am ET1min read
Faruqi & Faruqi, LLP is investigating potential claims against Novo Nordisk A/S for securities fraud between May 7, 2025, and July 28, 2025. The firm is encouraging investors who suffered losses to contact James (Josh) Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). The deadline to seek lead plaintiff status is September 30, 2025.
Investors who suffered losses related to Novo Nordisk A/S (NYSE: NVO) securities between May 7, 2025, and July 28, 2025, are being encouraged to contact legal firms investigating potential claims of securities fraud. The firms are urging investors to seek the role of lead plaintiff in a federal securities class action lawsuit by September 30, 2025.The Lawsuit Overview
The complaint filed against Novo Nordisk alleges that the company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose the true state of Novo's growth potential. Specifically, the complaint alleges that Novo Nordisk overstated its ability to capture patients coming off of compounded treatments and understated the potential impact of the personalization exception to the compounded GLP-1 exclusion. This led to materially misleading statements about the company's business, operations, and prospects [1].
Impact on Stock Price
Following the announcement of lower sales and profit outlooks on July 29, 2025, Novo Nordisk's stock price declined dramatically. The stock fell from $69.00 per share on July 28, 2025, to $53.94 per share on July 29, 2025, a decline of about 21.83% in a single day [1].
Investor Actions
Investors who suffered losses exceeding $100,000 during the specified period are encouraged to contact James (Josh) Wilson of Faruqi & Faruqi, LLP directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights [2]. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995 and is currently investigating potential claims against Novo Nordisk [2].
Lead Plaintiff Deadline
The deadline to seek lead plaintiff status in the lawsuit is September 30, 2025. Investors who wish to participate in the class action do not need to take any immediate action but can retain counsel of their choice or remain absent members of the class action [1].
Contact Information
For more information about the lawsuit, investors can visit www.faruqilaw.com/NVO or contact Faruqi & Faruqi partner Josh Wilson directly at the provided phone numbers. The firm also encourages anyone with information regarding Novo's conduct to contact them [2].
References
[1] https://www.marketscreener.com/news/novo-nordisk-a-s-nvo-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-ce7c51dcdb88f123
[2] https://www.prnewswire.com/news-releases/shareholder-action-reminder-faruqi--faruqi-llp-investigates-claims-on-behalf-of-investors-of-novo-ce7c51d3d08ef226
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet